Antibody Contract Manufacturing Market

Antibody Contract Manufacturing Market: Industry Trends and Global Forecasts, till 2035: Distribution by Type of Antibody Manufactured (Monoclonal and Bispecific), Type of Expression System Used (Mammalian and Microbial), Scale of Operation (Clinical and Commercial), and Geographical Regions (North America, Europe, Asia, Latin America and Middle East and North Africa)

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    208

  • Pages
    362

  • View Count
    8129

Antibody Contract Manufacturing Market Overview

The antibody contract manufacturing market size is projected to grow from $16.6 billion in 2024 to $47 billion by 2035, representing a CAGR of 10%, during the forecast period 2024-2035. The new research study consists of industry trends, detailed market analysis, market landscape of antibody contract manufacturers, company competitiveness analysis, benchmarking analysis, SWOT analysis, case studies, and capacity analysis. demand analysis, and market forecast and opportunity analysis. 

Antibody Contract Manufacturing Market by Key Geographical Regions, 2024-2035 (USD Billion)

To learn more about this report, request a free sample copy

The antibody contract manufacturing market is witnessing robust growth, propelled by several key drivers including demand for biologics, rising prevalence of chronic diseases and the trend towards personalized medicine. Since the approval of Orthoclone OKT3® in 1986, monoclonal antibodies have emerged as an important modality of healthcare industry. Notably, over 100 therapeutic monoclonal antibodies have received approval across various regions to date. Recent approvals include RYSTIGGO (June 2023), Columvi® (June 2023) and EPKINLY™ (May 2023). Due to their precise targeting and favorable safety profiles, therapeutic antibodies constitute the largest category of biologics used in the industry.

This dominance is expected to persist, as advanced antibodies such as bispecific antibodies and antibody fragments gain prominence. Additionally, challenges inherent in biologics development and production have led to a prevalent trend of outsourcing antibody production operations.

The market for antibody contract manufacturing or monoclonal antibody contract manufacturing is fiercely competitive, featuring companies of various sizes. It is worth mentioning that some players claim to provide comprehensive solutions, from antibody development to commercial production however, sponsors are likely to relay on contract service providers due to the significant costs and time associated with establishing biologics infrastructure and expertise. Competition among contract manufacturing organizations (CMOs) is intense, with access to cutting-edge tools and technologies being a crucial differentiator. Consequently, CMOs are expanding their capacities and capabilities to consolidate their positions in the market and meet the escalating demand for and reagents. With a growing pipeline of antibody-based therapeutics, substantial market growth is anticipated in the antibody contract manufacturing sector during the forecast period.

Antibody Contract Manufacturing Market Share Insights

The market report presents an in-depth analysis of the various service providers that are involved in the antibody manufacturing, across different segments, as defined in the table below:

Antibody Contract Manufacturing Market: Report Attributes / Market Segmentations

Key Report Attribute Details
Historical Trend 2019-2023
Base Year 2023
Forecast Period 2024-2035
Market Size Value in 2024 $16.6 Billion
Market Size Value by 2035 $47 Billion
Growth Rate CAGR of 10% from 2024 to 2035
Type of Antibody Manufactured
  • Monoclonal
  • Bispecific
Scale of Operation
  • Clinical
  • Commercial
Type of Expression System Used
  • Mammalian
  • Microbial
Geographical Regions
  • North America
  • Europe
  • Asia
  • Latin America
  • Middle East and North Africa
Leading Market Players
  • AGC Biologics
  • Aldevron
  • Emergent BioSolutions
  • Eurofins CDMO
  • FUJIFILM Diosynth Biotechnologies
  • KBI Biopharma
  • Lonza
  • Nitto Avecia Pharma Services
  • Novasep
  • Pierre Fabre
  • Samsung BioLogics
  • Synthon
  • Thermo Fisher Scientific
PowerPoint Presentation
(Complimentary)
Available
Customization Scope 15% Free Customization 
Excel Data Packs
(Complimentary)
  • Market Landscape Analysis
  • Company Competitiveness Analysis
  • Benchmarking Analysis
  • Capacity Analysis
  • Demand Analysis
  • Market Size and Opportunity Analysis

One of the key objectives of this market report was to estimate the current market size, opportunity and the future market growth potential of the service providers in the antibody CMO market, over the forecast period. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period 2024-2035. 

The market report also features the likely distribution of the current and forecasted opportunity for service providers in the global market across various segments, such as type of antibody (monoclonal and bispecific), scale of operation (clinical and commercial), type of expression system used (mammalian and Microbial) and key geographical regions (North America, Europe, Asia, Latin America and Middle East and North Africa). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three antibody contract manufacturing market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s evolution.

The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Chief Executive Officer, Mid-sized Company, Austria
  • Assistant Marketing Manager, Mid-sized company, Netherlands
  • Business Development Specialist, Mid-sized Company, Poland
  • Business Development Manager, Mid-sized, Germany
  • Business Development Manager, Mid-sized, Taiwan
  • Business Development and Marketing Manager, Mid-sized Company, Spain

Further, all actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Antibody Contract Manufacturing Market Key Segments

Market Share by Type of Antibody

The global antibody CMO market is segmented into different types of antibodies, namely monoclonal antibody, and bispecific antibody. Monoclonal antibodies are likely to occupy the highest share in 2024 and is expected to remain dominant during the forecast period. This can be attributed to the fact that monoclonal antibodies typically have a simpler structure compared to bispecific antibodies. This simplicity often translates into more straightforward manufacturing processes, which can be advantageous for contract manufacturers saving their cost and time.

Market Share by Scale of Operation

This segment highlights the distribution of antibody CMO market across clinical and commercial scales of operation. Owing to the fact that the demand for commercial production of antibodies is higher than that of clinical stage antibodies, therefore antibody contract manufacturing market at commercial scale captures the majority share in 2024. 

Market Share by Type of Expression System Used

The global antibody contract manufacturing market growth is dependent on the type of expression system used. This can be attributed to the fact expression systems are crucial in producing therapeutic antibodies, and different systems offer various advantages and limitations in terms of yield, quality, scalability, and cost-effectiveness. It is worth highlighting that, presently, majority of the market value is occupied by mammalian expression system during the forecast period. This can be attributed to the fact that antibodies produced in mammalian cells often exhibit higher biological activity and binding affinity compared to those produced in microbial cells. This is particularly important for therapeutic antibodies intended for clinical use, where potency and efficacy are critical factors.

Market Share by Key Geographical Regions

This segment highlights the opportunity associated with the antibody contract manufacturing market across key geographies, namely North America, Europe, Asia, Latin America and Middle East and North Africa. According to our projections, presently, North America is likely to capture majority (55%) of the global market share, and this trend is unlikely to change in the future as well. It is worth highlighting that the antibody CMO market in Asia is expected to grow at a relatively higher CAGR (12%), during the forecast period, 2024-2035.

Antibody Contract Manufacturing Market Key Insights

The “Antibody Contract Manufacturing Market, 2024-2035: Distribution by type of antibody (monoclonal and bispecific), scale of operation (clinical and commercial), type of expression system used (mammalian and Microbial) and key geographical regions (North America, Europe, Asia, Latin America and Middle East and North Africa): Industry Trends and Global Forecasts” report features an extensive study of the current market landscape, market size and future opportunity within the antibody CMO market for service providers, during the given forecast period. The market report highlights the efforts of several stakeholders involved in this rapidly emerging segment of the service providers industry. Key takeaways of the antibody contract manufacturing market report are briefly discussed below.

Advantages of Outsourcing Antibody Manufacturing

The service providers in the antibody CMO market have a well-established service portfolio, experienced tech-support team, access to expertise and capabilities related to different technology platforms. In addition, outsourcing leverages flexibility and scalability needed to navigate dynamic market landscape without the burden of infrastructure investment. This is particularly valuable for projects with changing requirements or companies in the early stages of development. Further, outsourcing can expedite the production timeline, as specialized manufacturers have streamlined processes and protocols in place, leading to quicker turnaround times compared to internal production. 

Further, outsourcing antibody manufacturing brings additional advantages such as leveraging cutting-edge technologies and accessing global markets, alongside risk reduction through established quality assurance systems and regulatory compliance expertise. Overall, it offers strategic and operational benefits, including cost optimization, accelerated timelines, risk mitigation, and enhanced quality assurance, enabling companies to concentrate resources on core activities and navigate the competitive biopharmaceutical landscape more effectively.

Competitive Landscape of Service Providers in the Antibody Contract Manufacturing Market

The current market landscape features the presence of over 125 contract service providers offering a variety of services related to antibody contract manufacturing; these include manufacturing services at clinical and commercial scale of operation, type of antibody manufactured (monoclonal and bispecific), type of expression systems used (mammalian and microbial), and fill / finish services offered. 

Further, the antibody CMO market features the presence of small, mid-sized and large and very large companies having the required expertise to offer contract manufacturing services across the globe. 

Key Drivers of Antibody Contract Manufacturing Market 

The antibody contract manufacturing market growth is primarily driven by the increasing demand for biopharmaceuticals, particularly monoclonal antibodies. As the prevalence of chronic diseases rises globally and the need for personalized medicine grows, there is a heightened demand for monoclonal antibodies, which are crucial therapeutic agents in treating various ailments including cancer, autoimmune disorders, and infectious diseases.  Further, advancements in biotechnology and recombinant DNA technology have led to the development of novel antibody-based therapeutics. These advancements have expanded the potential applications of antibodies, spurring the demand for contract manufacturing services to meet production requirements efficiently and cost-effectively.

Furthermore, the increasing emphasis of regulatory agencies on ensuring product quality, safety, and compliance with Good Manufacturing Practices standards has intensified the need for reliable and experienced CMOs with established quality management systems. Pharmaceutical companies seek CMO partners with a proven track record of regulatory compliance to navigate the complexities of regulatory requirements efficiently.

Antibody Contract Manufacturing Market Size

The global antibody manufacturing market for antibody contract manufacturing services is estimated to be $16.6 billion in 2024. In terms of the type of antibody, the market size for monoclonal antibodies is anticipated to grow at a relatively higher CAGR of 10% during the forecast period 2024-2035. The market growth is primarily fueled by increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases. As the demand for therapeutic antibodies grows, pharmaceutical and biotechnology companies seek outsourcing partners with expertise in antibody production to meet their manufacturing needs efficiently and cost-effectively.

Regional Analysis: North America Holds the Largest Antibody Contract Manufacturing Market Share

Presently, 55% of the antibody CMO market is captured by North America. This can be attributed to expansion of manufacturing facilities by various players in US. Additionally, the substantial investment flowing into North America's biopharma sector further bolsters demand for CMO services, facilitating collaboration and innovation. Further, the market value for antibody contract manufacturing in Asia-Pacific is expected to grow at a relatively higher CAGR of 12% during the forecast period. 

Leading Service Providers in the Antibody Contract Manufacturing Market 

Examples of key service providers involved in the antibody contract manufacturing industry (which have also been captured in this market report, arranged in alphabetical order) include AGC Biologics, Aldevron, Emergent BioSolutions, Eurofins CDMO, FUJIFILM Diosynth Biotechnologies, KBI Biopharma, Lonza, Nitto Avecia Pharma Services, Novasep, Pierre Fabre, Samsung BioLogics, Synthon and Thermo Fisher Scientific.

Antibody Contract Manufacturing Market Report Coverage

The market report presents an in-depth antibody contract manufacturing market analysis, highlighting the capabilities of various service providers in this global market, across different segments. Amongst other elements, the market report includes:

  • A preface providing an introduction to the full report, Antibody Contract Manufacturing Market (2nd edition), 2019-2023 (Historical Trends) and 2024-2035 (Forecasted Estimates).
Antibody Contract Manufacturing Market List Antibody Contract Manufacturing Market Competitiveness Antibody Contract Manufacturing Market Partnerships
  • An outline of the systematic research methodology adopted to conduct the study on antibody contract manufacturing industry, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
  • An overview of economic factors that impact the overall service providers in the antibody contract manufacturing market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
  • An executive summary of the insights captured during our research. It offers a high-level view on the current state of services offered by service providers for antibody contract manufacturing and its likely evolution in the mid-long term.
  • A general overview of antibody contract manufacturing, highlighting details on structure and mechanism of action of antibodies, various types of antibodies along with their applications. Additionally, the chapter includes a brief overview of contract manufacturing with their advantages and rising need.
  • A detailed review of the overall landscape of companies, offering contract services for the manufacturing of antibodies, along with information on year of establishment, company size, location of headquarters, location of manufacturing facilities, scale of operation (preclinical, clinical and commercial), type of antibody (monoclonal antibodies, bispecific antibodies and polyclonal antibodies), type of expression systems used (mammalian, microbial and others), fill / finish operations and affiliations to regulatory agencies. 
  • A company competitiveness analysis of key players in this domain, based on their company strength (related to the experience of a contract manufacturer), portfolio strength (which takes into account scale of operation, type of expression system used, and fill / finish services offered) and portfolio diversity (which consider type of antibody manufactured).
  • Elaborate profiles of key service providers in antibody contract manufacturing market. Each profile features a brief overview of the antibody contract manufacturing service providers, along with information on location of headquarters, year of establishment, number of employees, leadership team, service portfolio, financial information (if available), recent developments, and an informed future outlook.
  • A detailed case study comparing the key characteristics of large and small molecule drugs, along with information on the steps and challenges involved in their respective manufacturing processes.
  • A benchmark analysis, highlighting the key focus areas of small, mid-sized, large and very large companies, comparing their existing capabilities within and beyond their respective (geography-based) peer groups.
  • An estimate of the overall, installed capacity for manufacturing antibodies based on data reported by industry stakeholders in the public domain; it highlights the distribution of available antibody production capacity on the basis of company size (small, mid-sized, large and very large firms) and key geographical regions (North America, Europe, Asia). 
  • Informed estimates of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.
Antibody Contract Manufacturing Market Capacity Analysis Antibody Contract Manufacturing Market Demand and Supply Antibody Contract Manufacturing Market Geographical
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.
  • A detailed estimate of the current market size and the future market growth potential of the antibody contract manufacturing market over the next decade. Based on multiple parameters, such as likely adoption trends and through reliable secondary and primary validations, we have provided an informed estimate on the market evolution during the forecast period 2024-2035. The report also features the likely distribution of the current and forecasted opportunity within the antibody contract manufacturing industry. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the market growth.
  • Detailed projections of the current and future opportunity for service providers in the antibody contract manufacturing market across various types of antibody, namely monoclonal antibodies and bispecific antibodies.
  • Detailed projections of the current and future opportunity for service providers in the antibody contract manufacturing market across various scales of operation, namely clinical and commercial.
  • Detailed projections of the current and future opportunity for service providers in the antibody contract manufacturing market across types of expression system used, namely mammalian and Microbial.
  • Detailed projections of the current and future opportunity for service providers in the antibody contract manufacturing market across different key geographical regions, namely North America, Europe, Asia, Latin America and Middle East and North Africa. 
Antibody Contract Manufacturing Market Major Sub Segment Antibody Contract Manufacturing Market Movement Analysis Antibody Contract Manufacturing Market Penetration

Recent Developments In Antibody Contract Manufacturing Market

Several recent developments have taken place in the market, some of which have been outlined below. These developments, even though they took place post the release of our antibody contract manufacturing market report, substantiate the overall market trends that we have outlined in our analyses

  • In February 2024, AbbVie entered into a collaboration with OSE Immunotherapeutics with an aim to develop OSE-230, a novel monoclonal antibody for the treatment of patients suffering from chronic inflammation.
  • In January 2024, WuXi Biologics signed research service agreement with BioNTech for discovering investigational monoclonal antibodies for developing next-generation therapeutic product candidates.
  • In January 2024, Eurofins CDMO announced the successful completion of its pilot-scale biologics development facility dedicated to the development and scaling of monoclonal antibodies and other mammalian-based therapeutic proteins.

Author(s): Ronit Sharma and Rupali Bhardwaj

Frequently Asked Questions

Question 1: What is antibody contract manufacturing?

Answer: Antibody Contract Manufacturing refers to manufacturing services provided by contract manufacturers to pharmaceutical product manufacturers for the development of bulk antibodies.

Question 2: How big is the antibody contract manufacturing market?

Answer: The antibody contract manufacturing market size is projected to grow from $16.6 billion in 2024 to $47 billion by 2035.

Question 3: What is the growth rate (CAGR) of the antibody contract manufacturing market?

Answer: The antibody CMO market is expected to grow at CAGR of 10% during the forecast period 2024-2035.

Question 4: Which region holds the largest market share in the antibody contract manufacturing market?

Answer: North America dominated with around 55% of the market share.

Question 5: Which segments hold the largest market share in the antibody contract manufacturing market?

Answer: Monoclonal antibodies hold the largest market share in 2024.

Question 6: What are the driving factors in the antibody contract manufacturing market?

Answer: Increasing demand for biopharmaceuticals, technological advancements that have led to development of more complex biologics, and strict regulatory standards.

Question 7: Who are the leading service providers in the antibody contract manufacturing market?

Answer: The leading service providers in the antibody contract manufacturing market are AGC Biologics, Aldevron, Emergent BioSolutions, Eurofins CDMO, FUJIFILM Diosynth Biotechnologies, KBI Biopharma, Lonza, Nitto Avecia Pharma Services, Novasep, Pierre Fabre, Samsung BioLogics, Synthon and Thermo Fisher Scientific.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com